Table 1.

Modulation of genes that exhibit robust responses to MS417 across cancer cell lines

Cell lineHEXIM1SERPINI1ZCCHC24ZMYND8MYCRGS2CDKN1AGADD45BBTG1BRD2FGFR3EFNB2HDAC9RIN2
NCI-H4601.751.621.770.161.310.790.801.661.651.602.673.19NTNT
DLD-11.843.933.820.230.411.663.631.832.351.711.391.52NT0.19
GEO2.285.191.880.200.341.721.981.341.551.551.080.800.550.16
NCI-H19752.779.301.980.18NT2.201.991.601.151.482.351.780.370.19
MDA-MB-2311.803.352.740.190.571.796.331.671.782.102.952.190.380.13
PC-3M1.942.671.890.17NT1.394.302.071.311.390.922.570.360.15
OPM24.021.773.360.320.08NTNTNTNTNT0.35NT0.37ND
MV4:113.368.691.760.450.22NTNTNTNTNT1.10NTNDND
HPAC3.678.945.170.17NT1.201.882.281.191.737.981.360.28NT
Ramos3.092.243.080.37NT1.26ND1.371.421.782.123.000.43NT
  • NOTE: Ten cancer cell lines were treated with DMSO or 0.5 ╬╝mol/L MS417 for 6 hours, and the expression of the 14 potential pharmacodynamic markers was determined using the QuantiGene Plex Assay. Expression change of each gene under MS417 treatment over DMSO is presented.

  • Abbreviations: ND, not detectable; NT, not tested.